The Community Blood Center (Appleton, WI) to Roll out biolog-id’s Technology to Support Platelet Lifecycle Management
8.11.2021 18:04:00 EET | Business Wire | Press release
Biolog-id LLC, a developer and service provider of connected healthcare solutions, announces today its partnership with The Community Blood Center, the sole provider of blood, platelets and plasma to nearly 30 hospitals throughout the Midwest. Committed to providing the highest safety and quality blood products, The Community Blood Center will deploy biolog-id’s technology to further improve platelet manufacturing, documentation, and inventory availability.
Due to their short shelf life (5-7 days), these lifesaving blood products require high manufacturing standards and optimized inventory management to maximize availability and minimize waste. Biolog-id’s platelet lifecycle management solution enhances operational excellence by optimizing throughout, streamlining documentation, and improving visibility to current and future inventory. This solution was developed to support multiple platelet manufacturing strategies based on the new FDA guidance.
“We are excited to have The Community Blood Center join the growing family of innovative blood centers who trust our solution,” said Amit Mayer, Chief Innovation Officer at biolog-id. “We are proud to support the challenging and critically important role of these blood centers for their hospitals and their communities.”
“The extremely short shelf life of platelets makes this a precious and critical resource, donated by committed blood donors,” said Kristine Belanger, Chief Operating Officer and Vice President, Operations at The Community Blood Center. “Our obligation is to get these, and all products, to the patients who rely on them in the most effective way possible. The biolog-id technology allows us to improve the efficiency of this process and help us fulfill our obligation to donors and patients.”
A customer-centric innovation focus, and a flexible technological platform, allows biolog-id to adapt its solution to the changing conditions of the healthcare landscape. The ability to easily configure its solution across different facilities, organizations and countries has been key to the expanding customer base in the US and worldwide.
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies. Company URL: www.biolog-id.com
About The Community Blood Center:
The Community Blood Center (CBC) was established in 1955 and continues today as an independent nonprofit providing a safe and reliable blood supply to hospitals in the Midwest. CBC has donor centers in Wisconsin (Appleton, Oshkosh, Little Chute and Woodruff) and is opening a donor center in Chicago, Ill. in 2022. CBC hosts more than 100 blood drives every month. The Community Blood Center is a member of America’s Blood Centers (ABC) and Blood Centers of America (BCA) which are networks of independent community-based, not-for-profit blood centers supporting the blood needs for approximately 60% of the United States. For more information: www.communityblood.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005747/en/
Contact information
Contacts – biolog-id:
Amit Mayer,
amitm@biologllc.com
Astrid Billard, astrid.billard@biolog-id.com
Contact –The Community Blood Center :
Juliana Jarchow, jjarchow@communityblood.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartsheet Unveils vsActual: The AI-Native Platform that Connects Strategy to Execution at ENGAGE 20264.11.2026 19:00:00 EET | Press release
Smartsheet, the AI-powered enterprise work management platform, today unveiled a new AI-native strategic planning and execution product at ENGAGE 2026, its annual customer conference. vsActual is designed to solve the two biggest obstacles to enterprise execution: siloed work scattered across disconnected systems and teams, and the manual tracking and reporting that keeps individuals and executives from seeing problems until it’s too late. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104989965/en/ Today, Smartsheet unveiled a new AI-native strategic planning and execution product, vsActual. AI is helping individuals move faster than ever, but it's also making it harder to keep everyone moving in the same direction. In fact, a PMI research report found that leaders cited the disconnect between planning and execution as the biggest barrier to reinventing their businesses, and VentureBeat Intelligence found that 64% of res
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 19:00:00 EET | Press release
SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstration. Thales Alenia Space supported system assembly, integration, testing and operation
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom